Argentina

Argentina's primary health regulatory authority is the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT), established under Decree 1490/1992 and operating under the jurisdiction of the Ministry of Health (Ministerio de Salud de la Nación). ANMAT is responsible for the authorization, registration, surveillance, and quality control of pharmaceuticals, medical devices, in vitro diagnostics, and digital health products marketed in the country. The general approval process requires product registration prior to commercialization, with applicants submitting a formal dossier to the relevant ANMAT department: the Instituto Nacional de Medicamentos (INAME) for pharmaceuticals, and the Instituto Nacional de Tecnología Médica (INTEMED) for medical devices and diagnostics. Risk-based classification systems are applied across product categories, with higher-risk products subject to more rigorous technical review.

Key submission requirements include the appointment of a local regulatory representative (apoderado técnico) who must be domiciled in Argentina and is legally responsible for the product's compliance throughout its lifecycle. ANMAT generally accepts dossiers aligned with the Common Technical Document (CTD) format for pharmaceuticals, and follows MERCOSUR harmonized technical standards for medical devices, referencing ISO, IEC, and IMDRF frameworks as applicable. Argentina participates in MERCOSUR regulatory harmonization initiatives, which can facilitate mutual recognition pathways with Brazil, Paraguay, and Uruguay. Notable recent reforms include the digitalization of registration submissions through the ANMAT online portal (SUIR), expedited review pathways for innovative or priority health technologies introduced during the COVID-19 pandemic, and ongoing alignment efforts with international regulatory convergence bodies such as IMDRF and PAHO's regional harmonization network (PANDRH).

Public procurement of health products in Argentina operates through a multi-layered federal structure. At the national level, the Ministerio de Salud de la Nación coordinates centralized purchasing for priority health programs, with procurement processes governed by the Ley de Contrataciones del Estado (Law 22.460 and its updates) and administered through the Oficina Nacional de Contrataciones (ONC). The national government conducts centralized tenders (licitaciones) for vaccines, essential medicines, and strategic medical supplies through entities such as the Fondo Estratégico de Salud and, for specific programs, through PAMI (the national social health insurer for retirees, one of the largest single purchasers in the country). Argentina's 23 provinces and the Autonomous City of Buenos Aires retain significant autonomous procurement authority, managing their own hospital and clinic supply chains through provincial health ministries and conducting independent tenders, which creates a fragmented landscape requiring engagement at both national and sub-national levels.

The private sector represents a substantial share of the Argentine health market, encompassing obras sociales (mandatory employment-based health insurers regulated by the Superintendencia de Servicios de Salud), prepaid health plans (medicina prepaga regulated under Law 26.682), and direct private hospital procurement. These entities negotiate pricing and formulary inclusion independently, making private market access a parallel and commercially significant channel. Argentina also participates in procurement mechanisms coordinated by international organizations including PAHO/WHO revolving funds for vaccines and essential medicines, and has historically received donor support through UNICEF and the Global Fund for programs targeting HIV/AIDS, tuberculosis, and malaria. Local manufacturing preference policies exist within the national industrial promotion framework, with measures encouraging domestic production through price preferences in public tenders and incentives under the Ministerio de Desarrollo Productivo, reflecting Argentina's longstanding tradition of local pharmaceutical and device manufacturing capacity.